-
-
-
-
-
-
-
Canaccord Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
-
-
-
-
-
-
Alnylam Pharmaceuticals (ALNY) PT Lowered to $447 at Bernstein SocGen Group
-
-
-
-
-
-
-
BofA on Alnylam (ALNY): 'AI-enabled diagnostics will help increase diagnosis rates'
-
-
-
-
-
-
-
Alnylam Pharmaceuticals (ALNY) PT Lowered to $450 at RBC Capital
-
-
-
-
-
-
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $529 at Needham
-
-
-
-
-
-
-
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026
-
-
-
-
-
-
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $472 at Raymond James
-
428,617 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

